CN1519017A - Combination of Chinese traditional medicine for treating menorrhagia as well as pharmaceutics and preparation method - Google Patents

Combination of Chinese traditional medicine for treating menorrhagia as well as pharmaceutics and preparation method Download PDF

Info

Publication number
CN1519017A
CN1519017A CNA031562906A CN03156290A CN1519017A CN 1519017 A CN1519017 A CN 1519017A CN A031562906 A CNA031562906 A CN A031562906A CN 03156290 A CN03156290 A CN 03156290A CN 1519017 A CN1519017 A CN 1519017A
Authority
CN
China
Prior art keywords
weight portion
radix
pharmaceutical composition
group
extractum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA031562906A
Other languages
Chinese (zh)
Other versions
CN1208085C (en
Inventor
徐志华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LIYI XINSHIDAI MEDICAL INDUSTRIAL Co Ltd
Original Assignee
LIYI XINSHIDAI MEDICAL INDUSTRIAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LIYI XINSHIDAI MEDICAL INDUSTRIAL Co Ltd filed Critical LIYI XINSHIDAI MEDICAL INDUSTRIAL Co Ltd
Priority to CNB031562906A priority Critical patent/CN1208085C/en
Priority to PCT/CN2004/000778 priority patent/WO2005021016A1/en
Priority to CNB2004800009015A priority patent/CN1290553C/en
Publication of CN1519017A publication Critical patent/CN1519017A/en
Application granted granted Critical
Publication of CN1208085C publication Critical patent/CN1208085C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/739—Sanguisorba (burnet)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/744—Gardenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A Chinese medicine for treating menorrhagia is prepared from 6-16 Chinese-medicinal materials including sanguisorba root, eclipta, capejasmine fruit, sophora flower, etc through extracting in alcohol or decocting.

Description

The menorrheal Chinese medicine composition of a kind of treatment and preparation and preparation method
Technical field
The present invention relates to a kind of Chinese medicine composition, belong to medical technical field, be specifically related to treat menorrheal Chinese medicine composition and pharmaceutical preparation thereof and preparation method.
Background technology
Menstrual cycle is constant, and that row surpasses through amount is normal, or the time lengthening of passing through, and amount also thereby increase is called " menorrhagia ", and menorrheal pathogeny mainly is due to the deficiency of vital energy or the heat in blood.It is contained because of being that natural endowment is plain, excess of YANG QI, and the arrogant heat of then giving birth to, heat then blood oozing from the body openings or subcuta neous tissue is not kept and is increased; Or the hot dry product of surfeit, accumulation of heat in CHONG and REN meridians, the absurd row of forcing blood causes and makes blood volume add.Clinical treatment is many with clearing away heat and cooling blood.Represent Fang You soup (" women section criterion ") in advance, square medicine is made up of the Radix Rehmanniae, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Rhizoma Chuanxiong, Cortex Phellodendri, the Rhizoma Anemarrhenae, Rhizoma Coptidis, bar a kind of reed mentioned in ancient books, Colla Corii Asini, Folium Artemisiae Argyi, Rhizoma Cyperi, Radix Glycyrrhizae Preparata.
Menorrhagia is common clinical, frequently-occurring disease, treats more thorny.Chinese medicine accumulates rich experience finally in the long periods of treatment practice.But Shang Weiyou utilizes state-of-the-art technology and in conjunction with the modern Chinese medicine of modern preparation process.
Summary of the invention
One object of the present invention is to disclose the menorrheal Chinese medicine composition of a kind of new treatment; Another object of the present invention is to disclose a kind of Chinese medicine composition pharmaceutical preparation and preparation method for the treatment of hemorrhagic disease that prepare.
Pharmaceutical composition of the present invention contains the medical material (by weight) of following component:
Radix Sanguisorbae 1-400 weight portion, Herba Ecliptae 1-350 weight portion, Fructus Gardeniae 1-500 weight portion
Flos Sophorae 1-360 weight portion, Cacumen Platycladi 1-300 weight portion, Pollen Typhae 1-420 weight portion
The medical material that also can add following component in the pharmaceutical composition of the present invention:
Herba Agrimoniae 1-360 weight portion, Rhizoma Bistortae 1-380 weight portion, Radix Cirsii Japonici 1-260 weight portion,
Petiolus Trachycarpi 1-280 weight portion, Cortex Moutan 1-250 weight portion, Radix Rubiae 1-300 weight portion,
Radix Rehmanniae 1-360 weight portion, Radix Paeoniae Alba 1-200 weight portion, Radix Scutellariae 1-320 weight portion,
Rhizoma Osmundae 1-380 weight portion
Also can add Radix Angelicae Sinensis 1-300 weight portion in the pharmaceutical composition of the present invention
The composition of pharmaceutical composition of the present invention and proportioning can also be (by weight):
Radix Sanguisorbae 5-200 weight portion, Herba Ecliptae 5-180 weight portion, Fructus Gardeniae 5-260 weight portion,
Flos Sophorae 5-180 weight portion, Cacumen Platycladi 5-100 weight portion, Pollen Typhae 5-210 weight portion
Herba Agrimoniae 5-220 weight portion, Rhizoma Bistortae 5-120 weight portion, Radix Cirsii Japonici 5-100 weight portion,
Petiolus Trachycarpi 5-120 weight portion, Cortex Moutan 5-120 weight portion, Radix Rubiae 5-150 weight portion,
Radix Rehmanniae 5-180 weight portion, Radix Paeoniae Alba 5-100 weight portion, Radix Scutellariae 5-160 weight portion,
Rhizoma Osmundae 5-160 weight portion, Radix Angelicae Sinensis 5-100 weight portion
Radix Sanguisorbae, Fructus Gardeniae, Flos Sophorae, Cacumen Platycladi, Pollen Typhae were to fry to good during said medicine was formed, and Radix Rubiae is good with red Radix Rubiae.
With medicine of the present invention as raw material, add the different auxiliary material of pharmaceutically often using, adopt conventional preparation process, medication preparation of the present invention can be become different clinical medicine dosage forms, as granule, capsule, tablet, injection, tincture, suppository, pill, syrup, mixture, powder, lotion, membrane, drop pill etc.
The conventional medicine excipient that medicine of the present invention adds as required can be correctives, dispersant, binding agent, thickening agent, lubricant, diluent, disintegrating agent, antiseptic, coloring agent, solvent, increase in the middle of the agent with fixed attention etc. one or more.
The optimal formulation of medicine of the present invention is a granule, and its preparation method is: the medical material in above-mentioned arbitrary prescription with 40-60% alcohol reflux secondary, each 1-3 hour, is merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), and alcohol reflux liquid is added, additional ethanol left standstill 24 hours to containing the alcohol amount for 55-85%, filtered, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), adds dextrin and stevioside, mixing, vacuum drying is ground into fine powder, make granule, drying, promptly.
The present invention can strengthen the blood coagulation hemostatic function, strengthens the stripped contraction that reaches in the body uterus, and participates in the hormone and the adjusting in cycle.In addition, Da Jiliang medicine of the present invention also has antiinflammatory action.
Following experimental example is used to further specify the present invention.
Pharmaceutical preparation (5gkg of the present invention -1, 10gkg -1, and 20gkg -1) can shorten bleeding time and the clotting time of mice; Heavy dose of (16gkg -1) can obviously shorten the P of Rats RT time, but to PT time and the obviously influence of FDP amount nothing; Observe the influence of pharmaceutical preparation of the present invention, found that two dosage group (8gkg female underage rat sexual organ and gonadal hormone -1, 16gkg -1) to rat FSH, LH and E 2The different rising effect of degree is arranged; Observe pharmaceutical preparation of the present invention to the active influence of rat uterus, the result shows, through duodenal administration (2.5gkg -1, 5gkg -1And 10gkg -1) can obviously improve the active amplitude of rat uterus; Pharmaceutical preparation of the present invention (0.05g, 0.1g, 0.2g) all is significantly improved to the three-dimensional uterine contraction amplitude of rat, contraction frequency and energy; Heavy dose of pharmaceutical preparation (20gkg of the present invention -1) mice and rat are also had antiinflammatory action.
Experiment material: 1, animal Kunming mouse 19～23g; The SD rat, 180～240g; The female underage rat of SD, 130～160g is provided by Medical University Of Anhui's Experimental Animal Center, the quality certification number: real moving accurate No. 01 of Anhui doctor.2, medicine and reagent pharmaceutical preparation of the present invention (granule), the Anhui Prov. Inst. of Pharmacology provides, lot number: 000112, test used dosage and all refer to the crude drug amount; YUNNAN BAIYAO, YUNNAN BAIYAO Group Co.,Ltd product, lot number: 980614; Oxytocin inj, Shanghai Hefeng Pharmaceutical Co., Ltd.'s product, lot number: 990404, GONGXUENING JIAONANG, YUNNAN BAIYAO Group Co.,Ltd product, lot number: 980414; Diethylstilbestrol injection, Shanghai the 9th pharmaceutical factory.3, the desk-top self-balancing recorder of instrument (XWTD-264 type), Shanghai Dahua Instrument and Meter Plant's product; Isolated organ water bath with thermostatic control (10B-I), Zhenghai, Zhejiang telecommunication factory; Two road physiology monitors (LMS-2B type), Chengdu Instruement Factory's product.
Experimental technique and result
1, to the influence in mice bleeding time
Get 50 of mices, male and female half and half, 10 every group, being divided into is 5 groups, i.e. adjuvant group (isometric(al)), positive controls (YUNNAN BAIYAO 0.6gkg -1), three dosage groups of reagent (small dose group 5gkg -1, middle dosage group 10gkg -1, heavy dose of 20gkg -1).The Ig administration, continuous 7d, 45min after the last administration measures the hemorrhage bleeding time of mice with cutting the tail method.The result shows that the bleeding time of mice can be obviously shortened in pharmaceutical preparation of the present invention, sees Table 1.
The influence in table 1 pair mice bleeding time (X ± S)
Group Dosage/gkg -1 Number of animals/only Bleeding time/min
Adjuvant group YUNNAN BAIYAO group pharmaceutical preparation of the present invention (granule) group Deng capacity 0.6 5 10 20 ?10 ?10 ?10 ?10 ?10 14.0±3.68 6.80±1.81 **13.20±3.32 9.70±3.30 7.70±2.90 **
Compare with the adjuvant group, *P＜0.05, *P＜0.01
2, to the influence of clotting time of mice
Get 50 of mices, male and female half and half, 10 every group, being divided into is 5 groups, i.e. adjuvant group (isometric(al)), positive controls (YUNNAN BAIYAO 0.6gkg -1), three dosage groups of reagent (small dose group 5gkg -1, middle dosage group 10gkg -1, heavy dose of 20gkg -1).The Ig administration, continuous 7d, 45min after the last administration, surveying the clotting time of mice with capillary glass-tube method, is that the capillary glass-tube insertion mice ophthalmic corner of the eyes ball rear vein beard of 1mm is got blood with internal diameter promptly, gets blood to 5cm, fracture glass-tube once every 30s, check to have or not and coagulate the silk appearance, and the record clotting time.The result shows that the clotting time of mice can be obviously shortened in pharmaceutical preparation of the present invention (granule), sees Table 2.
The influence of table 2 pair clotting time of mice (X ± S)
Group Dosage/gkg -1 Number of animals/only Bleeding time/s
Adjuvant group YUNNAN BAIYAO group pharmaceutical preparation of the present invention (granule) group Deng capacity 0.6 5 10 20 10 10 10 10 10 64.10±13.11 44.90±12.11 **50.0±11.57 *43.0±10.50 **40.80±11.58 **
Compare with the adjuvant group, *P＜0.05, *P＜0.01
3, to the influence of P of Rats RT, PT and FDP
Get 50 of mices, male and female half and half, 10 every group, being divided into is 5 groups, i.e. adjuvant group (isometric(al)), positive controls (YUNNAN BAIYAO 0.6gkg -1), three dosage groups of reagent (small dose group 5gkg -1, middle dosage group 10gkg -1, heavy dose of 20gkg -1).The Ig administration, continuous 7d, 45min after the last administration gets blood in rat femoral, measures blood plasma recalcification time (PRT) and prothrombin time (PT, one-step method) respectively; Get blood 2ml, separation of serum is with the content of staphylococcus aggregation method mensuration rat blood serum fibrin degradation product (FDP) (FDP).The result shows that pharmaceutical preparation of the present invention (granule) can obviously be shortened the PRT time, but PT time and FDP amount are not had obviously influence, sees Table 3, table 4.
The influence of table 3 couple P of Rats RT and PT (X ± S)
Group Dosage/g kg -1 Number of animals/only PRT/min PT/s
PRP?????????????PPP
Adjuvant group YUNNAN BAIYAO group pharmaceutical preparation of the present invention (granule) group Deng capacity 0.6 5 10 20 10 10 10 10 10 6.37±1.12??????7.89±1.46 5.77±0.83??????5.25±0.69 **6.10±0.97??????7.67±0.84 5.74±0.80??????7.64±1.15 4024±1.11 **???5.46±0.61 ** 15.90±3.07 14.60±2.27 15.40±2.71 15.20±2.49 13.40±4.27
Compare with the adjuvant group, *P＜0.05, *P＜0.01
The influence of table 4 couple rat blood serum FDP (X ± S)
Group Dosage/gkg -1 Number of animals/only FDP amount/gml -1
Adjuvant group YUNNAN BAIYAO group pharmaceutical preparation of the present invention (granule) group Deng capacity 0.5 48 16 8 8 8 8 8 0.75±0.46 0.62±0.51 0.75±0.46 0.75±0.46 0.50±0.53
4, to the influence of mice RBC, WBC and PLT
Get 40 of mices, male and female half and half, 10 every group, being divided into is 4 groups, i.e. adjuvant group (isometric(al)), positive controls (YUNNAN BAIYAO 0.6gkg -1), two dosage groups of reagent (middle dosage group 10gkg -1And heavy dose of group 20gkg -1).The ig administration, continuous 7 days, 45min after the last administration, eyeball is got blood, conventional determining RBC, WBC and PLT.The result shows, pharmaceutical preparation of the present invention (granule) can raise RBC and WBC do not have obvious influence to PLT quantity, see Table 5.
The influence (X ± S, n=9,10) of table 5 couple mice RBC, WBC and PLT
Group Dosage/g kg -1 RBC /×10 12·L -1 WBC /×10 9·L -1 PLT /×10 9·L -1
Adjuvant group YUNNAN BAIYAO group pharmaceutical preparation of the present invention (granule) group Deng capacity 0.6 10 20 8.33±0.37 8.61±0.46 8.78±0.49 *8.91±0.46 2.59±0.32 2.88±0.74 3.35±0.87 *4.87±0.74 ** 652.70+175.14 555.50±290.96 568.88±223.35 636.50±139.66 ??????????????????
Compare with the adjuvant group, *P＜0.05, *P＜0.01
5, to the influence of female underage rat sexual organ and gonadal hormone
Get 40 of female underage rats, 10 every group, being divided into is 4 groups, i.e. adjuvant group (isometric(al)), positive controls (Herba Clinopodii Tabellae 0.6gkg -1), two dosage groups of reagent (middle dosage group 8gkg -1And heavy dose of group 16gkg -1).The ig administration, continuous 14 days, 45min after the last administration, abdominal aortic blood, separation of serum is surveyed serum estradiol (E with radioimmunology 2), the content of progesterone (P), follicle stimulating hormone (FSH) and lutropin (LH); The uterus and the ovary that separate rat claim weight in wet base, calculate organ coefficient, then with uterus and ovary formalin fixed, and the section of routine paraffin wax bag reason, HE dyeing microscopic examination.Found that uterus of four groups of mices and ovary all are hypertrophy late period or the early stage change of secretion, each organizes the interior all visible growth follicles of ovary and corpus luteum forms, but each does not see notable difference between organizing; Pharmaceutical preparation of the present invention (granule) does not have obvious influence to ovary and uterus weight; Pharmaceutical preparation of the present invention (granule) is to FSH, LH and E 2The different influence of degree is arranged, can increase its content, the adjustment process that has participated in hormone is described, see Table 6.
The influence (X ± S, n=8,9,10) of table 6 couple female underage rat sexual organ and gonadal hormone
Group Dosage/g kg -1 Uterus/mg 100g -1 Ovary/mg 100g -1 FSH /mIU LH mIU E2 /pg·ml -1 P /pg·ml -1
Adjuvant group YUNNAN BAIYAO group medicine of the present invention Deng capacity 0.6 10 139.92±10.31 141.12±36.18 140.63±35.74 48.04±14.31 46.47?±8.42 43.02±8.22 2.927±1.360 3.731±1.803 4.947±1.347 * 3.222±1.414 5.354±1.735 *6.832±1.50 ** 104.105±70.250 115.365±87.354 121.303±75.059 5.117±1.437 5.015±2.311 6.383±2.461
Thing preparation (granule) group 20 ?170.61±57.46 ?52.51±12.48 ?4.171±1.023 * 5.958±2.069 ** 143.949±72.045 ** 5.525±1.806
Compare with the adjuvant group, *P＜0.05, *P＜0.01
6, to the active influence of rat uterus
(1) isolated uterine test
Female unpregnancy SD rat experiment a few days ago, subcutaneous injection diethylstilbestrol 1mgkg -1, once a day, twice totally, rat execution was cut open the belly, find the uterus in the 3rd day, cut the wherein about 2cm of a side, careful separating uterus is put into the uterus isolated organ constant temperature water bath that fills 20ml De JalonII nutritional solution, the water bath bottom is fixed in the lower end, the upper end links to each other with transducer, passes to sufficient amount of oxygen, 1～2 bubble of per second, 31 ± 0.5 ℃ of temperature, constant temperature is connected (range 10mv, chart speed 2mm/min) with the transducer bath with desk-top balance recorder, temperature was bathed 60 minutes, after treating that uterine activity is stable, the record baseline adds medicine then, curvilinear motion behind the recording medicine, the amplitude before and after the mensuration medication, frequency and energy.The result shows that pharmaceutical preparation of the present invention (granule) can obviously improve the uterotonic frequency of isolated rat, amplitude and energy, sees Table 7.
The active influence of table 7 pair isolated uterine (X ± S, n=8)
Drug dose/ml Frequency/times 10 minutes -1 Amplitude/lattice Energy/time * lattice
Before the administration After the administration Before the administration After the administration Before the administration After the administration
The present invention's 0.05 pharmaceutical preparation 0.1 (granule) 0.2 ??3.625±0.916 ??3.625±1.060 ??6.250±2.121 ??8.125±0.834 **??7.50±1.511 **??8.625±1.060 * ??1.125±0.353 ??1.250±0.462 ??3.0±1.772 ??5.750?±2.492 **??10.625±3.420 **??20.125±7.989 ** ??4.125±1.807 ??4.25±1.035 ??21.125±15.132 ??46.875?±20.469 **??81.375±33.80 ??176.50±78.087 **
Oxytocin 0.1 ??3.625±1.922 ??11.250±1.832 ** ??1.250±0.462 ??18.750±5.725 ** ??5.125±4.517 ??215.375±89.748 **
With comparison before the administration, *P＜0.05, *P＜0.01
Annotate: 1, every lattice are 2.5mm.
2, oxytocin 5uml -1Pharmaceutical preparation of the present invention (granule) 1g crude drug ml -1
(2) test in the body uterus
Get 40 of female unpregnancy SD rats, body weight: 180～240g is divided into 5 groups at random, and adjuvant group, pharmaceutical preparation of the present invention (granule) (comprise 10gkg -1, 5gkg -1, 2.5gkg -1), GONGXUENING group (0.1gkg -1), respectively through duodenal administration 1ml100g -1, matched group gives the adjuvant of equal capacity; Test a few days ago, respectively subcutaneous injection diethylstilbestrol 1mgkg -1Once a day, totally twice, the three day, with 20% urethane 1gkg -1Intraperitoneal injection of anesthesia, dorsal position is fixed on the Mus plate, epigastrium median incision 1-2cm, seek and fixing duodenum, medicinal fully, hypogastric region median incision 2cm finds out the uterus, separates surrounding tissue, choose one section that is about 3cm at a side cornua uteri, mid point stitches a cotton thread in order to linking to each other with transducer, and the vagina end and the ovary end at angle, palace is separately fixed on the special glass infuser two ends fulcrum, and cotton thread is linked to each other with transducer, connect two road physiology monitor (time constants: 0.2, filtering 10HZ, sensitivity 0.5, chart speed 100mm/min).With operating lamp irradiation insulation, uterus load 1g, treat that uterine activity is stable after, trace normalized curve, then through duodenal administration, 10min, 30min, 90min uterine contraction curve after the record administration.The result shows that pharmaceutical preparation of the present invention (granule) can improve the amplitude of uterine activity, but contraction frequency is not had obvious influence, sees Table 8.
The table 8 pair influence at the body uterine activity (X ± S, n=8)
Group dosage/gkg -1 Frequency change rate/% Amplitude of variation rate/%
10???????????????????30’????????????????????????90’ ?????10’???????????????????????30’??????????????????????????????90’
Capacity-2.193 ± 4.897-3.579 ± 10.408-4.656 ± 15.550 2.105 ± 32.263-10.437 ± 18.654-41.002 ± 15.706 GONGXUENING group 0.1 1.896 ± 6.398 4.717 ± 9.232-0.520 ± 8.532 83.067 ± 34.068 such as adjuvant group **??96.896±46.208 **??5.495±31.495 **Medicine 2.5 1.626 ± 4.302-0.846 ± 5.786-7.110 of the present invention ± 8.193 29.313 ± 43.224 17.422 ± 41.998-2.342 ± 37.762 *Thing preparation 5 6.543 ± 14.234 0.550 ± 13.245-4.331 ± 14.123 75.193 ± 30.946 **??103.655±41.823 **?4.562±28.386 **(granule) 10 0.297 ± 11.856-4.663 ± 11.764-8.516 ± 10.164 105.322 ± 50.654 **?137.116±39.749 **?31.732±31.697 **
Compare with the adjuvant group, *P＜0.05, *P＜0.01
7, anti-inflammatory and antalgic test
(1) antiinflammatory test
Get 50 of mices, male and female half and half, 10 every group, being divided into is 5 groups, i.e. adjuvant group (isometric(al)), positive controls (indomethacin 9mg.kg -1), three dosage groups of reagent (small dose group 5g.kg -1, middle dosage group 10g.kg -1, heavy dose of group 20g.kg -1).The ig administration, continuous 7d, 30min after the last administration, be coated with 100% dimethylbenzene on ear two sides, a mice left side, auris dextra is put to death mice for contrast behind the 4h, cut two ears along the auricle baseline, prepare the mice auricle with 6mm diameter card punch, claim weight in wet base with electronic scale, with the difference of two ear weight as swelling degree (inflammation index).Found that heavy dose of inductive ear swelling degree of pharmaceutical preparation of the present invention (granule) xylol has obvious inhibitory action, sees Table 9.
The influence of the inductive ear swelling degree of table 9 pharmaceutical preparation of the present invention (granule) xylol (X ± S, n=8)
Group dosage ear swelling degree/gkg -1???/Δmg
Capacity 19.20 ± 4.31 indomethacins 9 12.50 ± 3.37 such as adjuvant group **Medicine 5 19.20 ± 4.61 thing preparations 10 20.70 ± 4.32 (granule) 20 14.60 ± 3.94 of the present invention *
Compare with the adjuvant group, *P＜0.05, *P＜0.01
Annotate: indomethacin dosage unit: mgkg -1, shared medicine 2 times.
Get 50 of rats, male and female half and half, 10 every group, being divided into is 5 groups, i.e. adjuvant group (isometric(al)), positive controls (indomethacin 3mg.kg -1), three dosage groups of reagent (small dose group 4g.kg -1, middle dosage group 8g.kg -1, heavy dose of group 16g.kg -1).The ig administration, continuous 10 days, the 1st day, prepare model in the time of the ig administration, promptly under the shallow fiber crops of ether, to form air bag, in air bag, inject genuine turpentine oil 1ml then at the scapular region of back SC20ml of every Mus air, extract the air in the capsule behind the 24h out.The 10th day, 30min put to death rat after the last administration, and peels off the wall internal granuloma, after the normal saline rinsing, claimed its dry weight after putting 80 ℃ of baking box 6h.Found that pharmaceutical preparation of the present invention (granule) has the obvious suppression effect to rat Oleum Terebinthinae air bag granulation hyperplasia, sees Table 10.
Table 10 pharmaceutical preparation of the present invention (granule) to the influence of rat Oleum Terebinthinae air bag granulation hyperplasia (X ± S, n=8)
Group dosage granuloma dry weight/gkg -1?/g
Capacity 1.11 ± 0.37 indomethacins 3 0.71 ± 0.22 such as adjuvant group *Medicine 4 1.00 ± 0.29 thing preparation 8 0.96 ± 0.29 (granule) 16 0.72 ± 0.18 of the present invention *
Compare with the adjuvant group, *P＜0.05
(2) analgesic test
On two models of mice hot plate method and mouse writhing method, there is no pharmaceutical preparation of the present invention (granule) has significant analgesia role.
Date processing adopts t check and variance analysis (q check).
Conclusion: pharmaceutical preparation of the present invention (granule) can strengthen the blood coagulation hemostatic function, strengthens the stripped contraction that reaches in the body uterus.And the participation hormone and the adjusting in cycle.In addition, Da Jiliang pharmaceutical preparation of the present invention (granule) also has antiinflammatory action.
The specific embodiment
Further specify the present invention by following examples, but it has no intention to limit the scope of patent application.Description in the following example all obtains by method known to those skilled in the art.
Embodiment 1:
Radix Sanguisorbae 10kg, Herba Ecliptae 10kg, Fructus Gardeniae 10kg,
Flos Sophorae 10kg, Cacumen Platycladi 10kg, Pollen Typhae 10kg
Above-mentioned Six-element medical material with 40-60% alcohol reflux secondary, each 1-3 hour, is merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), and alcohol reflux liquid is added, additional ethanol left standstill 24 hours to containing the alcohol amount for 55-85%, filtered, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), adds dextrin and stevioside, mixing, vacuum drying is ground into fine powder, make granule, drying, promptly.
Embodiment 2:
Radix Sanguisorbae 1kg, Herba Ecliptae 350kg, Fructus Gardeniae 500kg,
Flos Sophorae 360kg, Cacumen Platycladi 300kg, Pollen Typhae 420kg
Above-mentioned Six-element medical material with 40-60% alcohol reflux secondary, each 1-3 hour, is merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, and each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), and alcohol reflux liquid is added, and additional ethanol is 55-85% to containing the alcohol amount, left standstill 24 hours, and filtered, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), adds dextrin and stevioside, mixing, vacuum drying is ground into fine powder, makes granule, drying, the dress capsule gets final product.
Embodiment 3:
Radix Sanguisorbae 400kg, Herba Ecliptae 1kg, Fructus Gardeniae 500kg,
Flos Sophorae 360kg, Cacumen Platycladi 300kg, Pollen Typhae 420kg
Above-mentioned Six-element medical material with 40-60% alcohol reflux secondary, each 1-3 hour, is merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), and alcohol reflux liquid is added, additional ethanol left standstill 24 hours to containing the alcohol amount for 55-85%, filtered, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), adds dextrin and stevioside, mixing, vacuum drying is ground into fine powder, and tabletting gets final product.
Embodiment 4:
Radix Sanguisorbae 400kg, Herba Ecliptae 350kg, Fructus Gardeniae 1kg,
Flos Sophorae 360kg, Cacumen Platycladi 300kg, Pollen Typhae 420kg
Above-mentioned Six-element medical material with 40-60% alcohol reflux secondary, each 1-3 hour, is merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), and alcohol reflux liquid is added, and additional ethanol is 55-85% to containing the alcohol amount, left standstill 24 hours, filter, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), add water to the configuration total amount, make injection with common process and get final product.
Embodiment 5:
Radix Sanguisorbae 400kg, Herba Ecliptae 350kg, Fructus Gardeniae 500kg,
Flos Sophorae 1kg, Cacumen Platycladi 300kg, Pollen Typhae 420kg
Above-mentioned Six-element medical material with 40-60% alcohol reflux secondary, each 1-3 hour, is merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), and alcohol reflux liquid is added, and additional ethanol is 55-85% to containing the alcohol amount, left standstill 24 hours, filter, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), add the ethanol of normal concentration, make tincture with common process and get final product.
Embodiment 6:
Radix Sanguisorbae 400kg, Herba Ecliptae 350kg, Fructus Gardeniae 500kg,
Flos Sophorae 360kg, Cacumen Platycladi 1kg, Pollen Typhae 420kg
Above-mentioned Six-element medical material with 40-60% alcohol reflux secondary, each 1-3 hour, is merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), and alcohol reflux liquid is added, and additional ethanol is 55-85% to containing the alcohol amount, left standstill 24 hours, filter, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), add suitable substrate, make suppository and get final product.
Embodiment 7:
Radix Sanguisorbae 400kg, Herba Ecliptae 350kg, Fructus Gardeniae 500kg,
Flos Sophorae 360kg, Cacumen Platycladi 300kg, Pollen Typhae 420kg,
Above-mentioned ten Six-element medical materials with 40-60% alcohol reflux secondary, each 1-3 hour, are merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), and alcohol reflux liquid is added, additional ethanol left standstill 24 hours to containing the alcohol amount for 55-85%, filtered, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), adds dextrin, mixing, vacuum drying is ground into fine powder, is that adhesive is made honeyed pill and got final product with Mel.
Embodiment 8:
Radix Sanguisorbae 100kg, Herba Ecliptae 90kg, Fructus Gardeniae 130kg, Flos Sophorae 90kg,
Cacumen Platycladi 50kg, Pollen Typhae 105kg, Herba Agrimoniae 110kg, Rhizoma Bistortae 60kg,
Radix Cirsii Japonici 50kg, Petiolus Trachycarpi 60kg, Cortex Moutan 60kg, Radix Rubiae 125kg,
Radix Rehmanniae 90kg, Radix Paeoniae Alba 5kg, Radix Scutellariae 160kg, Rhizoma Osmundae 80kg
Above-mentioned ten Six-element medical materials with 40-60% alcohol reflux secondary, each 1-3 hour, are merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), and alcohol reflux liquid is added, additional ethanol is 55-85% to containing the alcohol amount, left standstill 24 hours, and filtered, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), add sucrose with water, make dense aqueous sucrose solution, promptly get syrup.
Embodiment 9:
Radix Sanguisorbae 100kg, Herba Ecliptae 90kg, Fructus Gardeniae 130kg, Flos Sophorae 90kg,
Cacumen Platycladi 50kg, Pollen Typhae 105kg, Herba Agrimoniae 110kg, Rhizoma Bistortae 60kg,
Radix Cirsii Japonici 50kg, Petiolus Trachycarpi 60kg, Cortex Moutan 60kg, Radix Rubiae 125kg,
Radix Rehmanniae 90kg, Radix Paeoniae Alba 50kg, Radix Scutellariae 5kg, Rhizoma Osmundae 80kg
Above-mentioned ten Six-element medical materials with 40-60% alcohol reflux secondary, each 1-3 hour, are merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), and alcohol reflux liquid is added, additional ethanol left standstill 24 hours to containing the alcohol amount for 55-85%, filtered, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), adds dextrin, mixing, vacuum drying is ground into fine powder, makes powder and gets final product.
Embodiment 10:
Radix Sanguisorbae 100kg, Herba Ecliptae 90kg, Fructus Gardeniae 130kg, Flos Sophorae 90kg,
Cacumen Platycladi 50kg, Pollen Typhae 105kg, Herba Agrimoniae 110kg, Rhizoma Bistortae 60kg,
Radix Cirsii Japonici 50kg, Petiolus Trachycarpi 60kg, Cortex Moutan 60kg, Radix Rubiae 125kg,
Radix Rehmanniae 90kg, Radix Paeoniae Alba 5kg, Radix Scutellariae 80kg, Rhizoma Osmundae 80kg,
Radix Angelicae Sinensis 50kg
Above-mentioned ten seven flavor medicine materials with 40-60% alcohol reflux secondary, each 1-3 hour, are merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), and alcohol reflux liquid is added, and additional ethanol is 55-85% to containing the alcohol amount, left standstill 24 hours, filter, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), add dextrin, water and suitable filmogen, be processed into membrane and get final product.
Embodiment 11:
Radix Sanguisorbae 5kg, Herba Ecliptae 180kg, Fructus Gardeniae 260kg, Flos Sophorae 180kg,
Cacumen Platycladi 100kg, Pollen Typhae 210kg, Herba Agrimoniae 220kg, Rhizoma Bistortae 120kg,
Radix Cirsii Japonici 100kg, Petiolus Trachycarpi 120kg, Cortex Moutan 120kg, Radix Rubiae 150kg,
Radix Rehmanniae 180kg, Radix Paeoniae Alba 100kg, Radix Scutellariae 160kg, Rhizoma Osmundae 160kg,
Radix Angelicae Sinensis 100kg
Above-mentioned ten seven flavor medicine materials with 40-60% alcohol reflux secondary, each 1-3 hour, are merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), adds ethanol, to containing the alcohol amount is 55～85%, leaves standstill 24 hours, filters, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), adds water to the configuration total amount, it is an amount of to add stevioside, filters fill, sterilization promptly gets oral liquid.
Embodiment 12:
Radix Sanguisorbae 5kg, Herba Ecliptae 5kg, Fructus Gardeniae 5kg, Flos Sophorae 5kg,
Cacumen Platycladi 5kg, Pollen Typhae 5kg, Herba Agrimoniae 5kg, Rhizoma Bistortae 5kg,
Radix Cirsii Japonici 5kg, Petiolus Trachycarpi 5kg, Cortex Moutan 5kg, Radix Rubiae 5kg,
Radix Rehmanniae 5kg, Radix Paeoniae Alba 5kg, Radix Scutellariae 5kg, Rhizoma Osmundae 5kg,
Radix Angelicae Sinensis 5kg
Above-mentioned ten seven flavor medicine materials with 40-60% alcohol reflux secondary, each 1-3 hour, are merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), adds ethanol, to containing the alcohol amount is 55～85%, leaves standstill 24 hours, filters, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), adds water to the configuration total amount, filter, fill, sterilization promptly gets lotion.
Embodiment 13:
Radix Sanguisorbae 200kg, Herba Ecliptae 180kg, Fructus Gardeniae 260kg, Flos Sophorae 180kg,
Cacumen Platycladi 100kg, Pollen Typhae 210kg, Herba Agrimoniae 220kg, Rhizoma Bistortae 120kg,
Radix Cirsii Japonici 100kg, Petiolus Trachycarpi 120kg, Cortex Moutan 120kg, Radix Rubiae 150kg,
Radix Rehmanniae 180kg, Radix Paeoniae Alba 100kg, Radix Scutellariae 160kg, Rhizoma Osmundae 160kg,
Radix Angelicae Sinensis 100kg
Above-mentioned ten seven flavor medicine materials with 40-60% alcohol reflux secondary, each 1-3 hour, are merged backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), adds ethanol, to containing the alcohol amount is 55～85%, left standstill 24 hours, and filtered, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), add dextrin, mixing is that substrate is made drop pill and got final product with the gelatin.

Claims (8)

1, the menorrheal pharmaceutical composition of a kind of treatment is characterized in that it contains the medical material of following component: Radix Sanguisorbae 1-400 weight portion, Herba Ecliptae 1-350 weight portion, Fructus Gardeniae 1-500 weight portion Flos Sophorae 1-360 weight portion, Cacumen Platycladi 1-300 weight portion, Pollen Typhae 1-420 weight portion
2, pharmaceutical composition as claimed in claim 1 is characterized in that it also can add the medical material of following component: Herba Agrimoniae 1-360 weight portion, Rhizoma Bistortae 1-380 weight portion, Radix Cirsii Japonici 1-260 weight portion, Petiolus Trachycarpi 1-280 weight portion, Cortex Moutan 1-250 weight portion, Radix Rubiae 1-300 weight portion, Radix Rehmanniae 1-360 weight portion, Radix Paeoniae Alba 1-200 weight portion, Radix Scutellariae 1-320 weight portion, Rhizoma Osmundae 1-380 weight portion
3, pharmaceutical composition as claimed in claim 2 is characterized in that it also can add Radix Angelicae Sinensis 1-300 weight portion.
4, pharmaceutical composition as claimed in claim 3, the proportioning of the medical material that it is characterized in that respectively distinguishing the flavor of in this pharmaceutical composition can also be:
Radix Sanguisorbae 5-200 weight portion Herba Ecliptae 5-180 weight portion Fructus Gardeniae 5-260 weight portion
Flos Sophorae 5-180 weight portion Cacumen Platycladi 5-100 weight portion Pollen Typhae 5-210 weight portion
Herba Agrimoniae 5-220 weight portion Rhizoma Bistortae 5-120 weight portion Radix Cirsii Japonici 5-100 weight portion
Petiolus Trachycarpi 5-120 weight portion Cortex Moutan 5-120 weight portion Radix Rubiae 5-150 weight portion
Radix Rehmanniae 5-180 weight portion Radix Paeoniae Alba 5-100 weight portion Radix Scutellariae 5-160 weight portion
Rhizoma Osmundae 5-160 weight portion Radix Angelicae Sinensis 5-100 weight portion
5, as claim 1,2,3 or 4 described pharmaceutical compositions, it is characterized in that Radix Sanguisorbae in this pharmaceutical composition, Fructus Gardeniae, Flos Sophorae, Cacumen Platycladi, Pollen Typhae to fry to good, Radix Rubiae is good with red Radix Rubiae.
6, as claim 1,2,3 or 4 described pharmaceutical compositions, it is characterized in that this pharmaceutical composition also can add excipient and make clinical acceptable any pharmaceutical dosage form, as granule, capsule, tablet, injection, tincture, suppository, pill, syrup, mixture, powder, lotion, membrane, drop pill etc.
7, said excipient can be correctives, dispersant, binding agent, thickening agent, lubricant, diluent, disintegrating agent, antiseptic, coloring agent, solvent, increase in the middle of the with fixed attention agent etc. one or more in the pharmaceutical composition as claimed in claim 6.
8, as claim 1,2,3,4 or 5 described preparation of drug combination methods, it is characterized in that this method is:
Get this compositions medical material with 40-60% alcohol reflux secondary, each 1-3 hour, merge backflow, filtration, filtrate for later use; Medicinal residues decoct with water secondary, each 1-3 hour, merge decoction liquor, filter, filtrate is concentrated into the extractum that relative density is 1.01～1.33 (80 ℃), and alcohol reflux liquid is added, and additional ethanol is 55-85% to containing the alcohol amount, left standstill 24 hours, filter, reclaim ethanol, being concentrated into relative density is the extractum of 1.01～1.33 (80 ℃), make various dosage forms with common process, get final product.
CNB031562906A 2003-09-03 2003-09-03 Combination of Chinese traditional medicine for treating menorrhagia as well as pharmaceutics and preparation method Expired - Lifetime CN1208085C (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CNB031562906A CN1208085C (en) 2003-09-03 2003-09-03 Combination of Chinese traditional medicine for treating menorrhagia as well as pharmaceutics and preparation method
PCT/CN2004/000778 WO2005021016A1 (en) 2003-09-03 2004-07-09 A pharmaceutical composition for treating hypermenorrhea and preparation method thereof
CNB2004800009015A CN1290553C (en) 2003-09-03 2004-07-09 Pharmaceutical composition for treating menorrhagia and method for preparing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB031562906A CN1208085C (en) 2003-09-03 2003-09-03 Combination of Chinese traditional medicine for treating menorrhagia as well as pharmaceutics and preparation method

Publications (2)

Publication Number Publication Date
CN1519017A true CN1519017A (en) 2004-08-11
CN1208085C CN1208085C (en) 2005-06-29

Family

ID=34240829

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB031562906A Expired - Lifetime CN1208085C (en) 2003-09-03 2003-09-03 Combination of Chinese traditional medicine for treating menorrhagia as well as pharmaceutics and preparation method
CNB2004800009015A Expired - Lifetime CN1290553C (en) 2003-09-03 2004-07-09 Pharmaceutical composition for treating menorrhagia and method for preparing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2004800009015A Expired - Lifetime CN1290553C (en) 2003-09-03 2004-07-09 Pharmaceutical composition for treating menorrhagia and method for preparing the same

Country Status (2)

Country Link
CN (2) CN1208085C (en)
WO (1) WO2005021016A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100394936C (en) * 2005-11-17 2008-06-18 西安千禾药业有限责任公司 Medicine for treating flooding and spotting and its preparation method
CN102343007A (en) * 2011-09-27 2012-02-08 江苏济川制药有限公司 Traditional Chinese medicine composition with hemostasis function
CN102626163A (en) * 2012-04-23 2012-08-08 北京绿源求证科技发展有限责任公司 Nutritious food menstruation regulating tea dissolved medicine beneficial for menstruation regulation
CN103784591A (en) * 2014-03-04 2014-05-14 张安美 Traditional Chinese medicine composition for postpartum care
CN105412493A (en) * 2016-01-18 2016-03-23 黄庆辉 Traditional Chinese medicine for treating blood-heat type hypermenorrhea
CN105582476A (en) * 2016-02-25 2016-05-18 林立朋 Pharmaceutical preparation for treating irregular menstruation and application thereof
CN105726850A (en) * 2016-05-02 2016-07-06 邹士东 Pharmaceutical preparation for treating burns, scalds and traumatic bleeding and preparation method thereof
CN105943774A (en) * 2016-05-01 2016-09-21 邹士东 Medicinal preparation for treating hypermenorrhea and preparation method of medicinal preparation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1814195B (en) * 2005-12-05 2011-04-06 杨雄志 Chinese medicine composition for treating gynecopathy and its preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1135905A (en) * 1995-05-18 1996-11-20 辽宁中医学院附属医院 Medicine for regulating menstruation
CN1203805A (en) * 1998-06-04 1999-01-06 李胤良 Health-care drink capable of preventing and curing menopathy

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100394936C (en) * 2005-11-17 2008-06-18 西安千禾药业有限责任公司 Medicine for treating flooding and spotting and its preparation method
CN102343007A (en) * 2011-09-27 2012-02-08 江苏济川制药有限公司 Traditional Chinese medicine composition with hemostasis function
CN102343007B (en) * 2011-09-27 2013-12-18 济川药业集团股份有限公司 Traditional Chinese medicine composition with hemostasis function
CN102626163A (en) * 2012-04-23 2012-08-08 北京绿源求证科技发展有限责任公司 Nutritious food menstruation regulating tea dissolved medicine beneficial for menstruation regulation
CN103784591A (en) * 2014-03-04 2014-05-14 张安美 Traditional Chinese medicine composition for postpartum care
CN103784591B (en) * 2014-03-04 2015-11-25 张安美 Postpartum care Chinese medicine composition
CN105412493A (en) * 2016-01-18 2016-03-23 黄庆辉 Traditional Chinese medicine for treating blood-heat type hypermenorrhea
CN105582476A (en) * 2016-02-25 2016-05-18 林立朋 Pharmaceutical preparation for treating irregular menstruation and application thereof
CN105943774A (en) * 2016-05-01 2016-09-21 邹士东 Medicinal preparation for treating hypermenorrhea and preparation method of medicinal preparation
CN105726850A (en) * 2016-05-02 2016-07-06 邹士东 Pharmaceutical preparation for treating burns, scalds and traumatic bleeding and preparation method thereof

Also Published As

Publication number Publication date
CN1290553C (en) 2006-12-20
CN1700927A (en) 2005-11-23
CN1208085C (en) 2005-06-29
WO2005021016A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
CN1208085C (en) Combination of Chinese traditional medicine for treating menorrhagia as well as pharmaceutics and preparation method
CN1806840A (en) Chinese medicinal compound preparation and its preparing process
CN102178828B (en) Medicament for treating proliferation of mammary gland and preparation method thereof
CN102085257B (en) Preparation method of micro-pills prepared from cassia twig and tuckahoe
CN102319398B (en) Blood-nourishing and eyesight-improving Chinese medicinal composition and preparation method thereof
CN104873675A (en) Pharmaceutical composition for treating swine high fever and preparation method thereof
CN102048890B (en) Traditional Chinese medicine composition with galactagogue effect and preparation method thereof
CN102048841B (en) Lactogenic traditional Chinese medicine composition and preparation method thereof
CN1853688A (en) Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof
CN1853689A (en) Chinese medicinal preparation for treating heart cerebrovascular disease and making method thereof
CN101642519B (en) Chinese patent medicine for treating mammary gland hyperplasia and preparation technique thereof
CN110237161B (en) Medicine for treating menopausal syndrome and preparation method and application thereof
CN101559196B (en) Medicament for treating the hyperplasia of mammary glands and preparation method thereof
CN103720943B (en) A kind of Chinese medicine for the treatment of gynecological bleeding and preparation method thereof
CN105288173A (en) Traditional Chinese medicine pellet preparation for regulating menstruation and removing freckles and preparation method thereof
CN110522841A (en) A kind of Chinese medicine composition and preparation method thereof, purposes
CN102018940B (en) Composition with lactogenic effect and preparation method and application thereof
CN1596907A (en) Use of bamboo leaf flavone in preparation of medicine or health-care food for preventing or treating thrombus disease or blood deficiency disease
CN1679742A (en) Medicine for treating dysmenorrhes and preparation thereof
CN1844132A (en) Method for extraction preparation of astragaloside
CN105749044A (en) Chinese herb preparation for treating chronic nephritis
CN1919253A (en) Cardiac and cerebral vascular disease treating medicinal composition
CN1919235A (en) Cardiac and cerebral vascular disease treating pharmaceutical composition
CN104162090A (en) Medicine composition and preparation method thereof
CN105748768A (en) Traditional Chinese medicinal composition for treating rheumatic analgesics, and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1065716

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20050629